Cargando…

Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center

BACKGROUND: Although mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines report >90% efficacy, breakthrough infections occur. Little is known about their effectiveness against SARS-CoV-2 variants, including the highly prevalent B.1.427/B.1.429 variant. METHODS: In thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobson, Karen B, Pinsky, Benjamin A, Montez Rath, Maria E, Wang, Hannah, Miller, Jacob A, Skhiri, Mehdi, Shepard, John, Mathew, Roshni, Lee, Grace, Bohman, Bryan, Parsonnet, Julie, Holubar, Marisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344553/
https://www.ncbi.nlm.nih.gov/pubmed/34137815
http://dx.doi.org/10.1093/cid/ciab554
_version_ 1783734482775310336
author Jacobson, Karen B
Pinsky, Benjamin A
Montez Rath, Maria E
Wang, Hannah
Miller, Jacob A
Skhiri, Mehdi
Shepard, John
Mathew, Roshni
Lee, Grace
Bohman, Bryan
Parsonnet, Julie
Holubar, Marisa
author_facet Jacobson, Karen B
Pinsky, Benjamin A
Montez Rath, Maria E
Wang, Hannah
Miller, Jacob A
Skhiri, Mehdi
Shepard, John
Mathew, Roshni
Lee, Grace
Bohman, Bryan
Parsonnet, Julie
Holubar, Marisa
author_sort Jacobson, Karen B
collection PubMed
description BACKGROUND: Although mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines report >90% efficacy, breakthrough infections occur. Little is known about their effectiveness against SARS-CoV-2 variants, including the highly prevalent B.1.427/B.1.429 variant. METHODS: In this quality improvement project, we collected demographic and clinical information from post-vaccine SARS-CoV-2 cases (PVSCs), defined as healthcare personnel (HCP) with positive SARS-CoV-2 nucleic acid amplification test after receiving ≥1 vaccine dose. Available specimens were tested for L452R, N501Y, and E484K mutations using reverse-transcription polymerase chain reaction. Mutation prevalence was compared among unvaccinated, early post-vaccinated (≤14 days after dose 1), partially vaccinated (positive test >14 days after dose 1 and <14 days after dose 2), and fully vaccinated (>14 days after dose 2) PVSCs. RESULTS: From December 2020 to April 2021, ≥23 090 HCP received ≥1 dose of an mRNA-based SARS-CoV-2 vaccine, and 660 HCP cases of SARS-CoV-2 occurred, of which 189 were PVSCs. Among the PVSCs, 114 (60.3%), 49 (25.9%), and 26 (13.8%) were early post-vaccination, partially vaccinated, and fully vaccinated, respectively. Of 261 available samples from vaccinated and unvaccinated HCP, 103 (39.5%), including 42 PVSCs (36.5%), had the L452R mutation presumptive of B.1.427/B.1.429. When adjusted for community prevalence of B.1.427/B.1.429, PVSCs did not have significantly elevated risk of B.1.427/B.1.429 compared with unvaccinated HCP. CONCLUSIONS: Most PVSCs occurred prior to expected onset of full, vaccine-derived immunity. Presumptive B.1.427/B.1.429 was not more prevalent in post-vaccine cases than in unvaccinated SARS-CoV-2 HCP. Continued infection control measures, particularly <14 days post-vaccination, and continued variant surveillance in PVSCs are imperative to control future SARS-CoV-2 surges.
format Online
Article
Text
id pubmed-8344553
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83445532021-08-10 Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center Jacobson, Karen B Pinsky, Benjamin A Montez Rath, Maria E Wang, Hannah Miller, Jacob A Skhiri, Mehdi Shepard, John Mathew, Roshni Lee, Grace Bohman, Bryan Parsonnet, Julie Holubar, Marisa Clin Infect Dis Major Articles and Commentaries BACKGROUND: Although mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines report >90% efficacy, breakthrough infections occur. Little is known about their effectiveness against SARS-CoV-2 variants, including the highly prevalent B.1.427/B.1.429 variant. METHODS: In this quality improvement project, we collected demographic and clinical information from post-vaccine SARS-CoV-2 cases (PVSCs), defined as healthcare personnel (HCP) with positive SARS-CoV-2 nucleic acid amplification test after receiving ≥1 vaccine dose. Available specimens were tested for L452R, N501Y, and E484K mutations using reverse-transcription polymerase chain reaction. Mutation prevalence was compared among unvaccinated, early post-vaccinated (≤14 days after dose 1), partially vaccinated (positive test >14 days after dose 1 and <14 days after dose 2), and fully vaccinated (>14 days after dose 2) PVSCs. RESULTS: From December 2020 to April 2021, ≥23 090 HCP received ≥1 dose of an mRNA-based SARS-CoV-2 vaccine, and 660 HCP cases of SARS-CoV-2 occurred, of which 189 were PVSCs. Among the PVSCs, 114 (60.3%), 49 (25.9%), and 26 (13.8%) were early post-vaccination, partially vaccinated, and fully vaccinated, respectively. Of 261 available samples from vaccinated and unvaccinated HCP, 103 (39.5%), including 42 PVSCs (36.5%), had the L452R mutation presumptive of B.1.427/B.1.429. When adjusted for community prevalence of B.1.427/B.1.429, PVSCs did not have significantly elevated risk of B.1.427/B.1.429 compared with unvaccinated HCP. CONCLUSIONS: Most PVSCs occurred prior to expected onset of full, vaccine-derived immunity. Presumptive B.1.427/B.1.429 was not more prevalent in post-vaccine cases than in unvaccinated SARS-CoV-2 HCP. Continued infection control measures, particularly <14 days post-vaccination, and continued variant surveillance in PVSCs are imperative to control future SARS-CoV-2 surges. Oxford University Press 2021-06-17 /pmc/articles/PMC8344553/ /pubmed/34137815 http://dx.doi.org/10.1093/cid/ciab554 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Articles and Commentaries
Jacobson, Karen B
Pinsky, Benjamin A
Montez Rath, Maria E
Wang, Hannah
Miller, Jacob A
Skhiri, Mehdi
Shepard, John
Mathew, Roshni
Lee, Grace
Bohman, Bryan
Parsonnet, Julie
Holubar, Marisa
Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center
title Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center
title_full Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center
title_fullStr Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center
title_full_unstemmed Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center
title_short Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center
title_sort post-vaccination severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections and incidence of the presumptive b.1.427/b.1.429 variant among healthcare personnel at a northern california academic medical center
topic Major Articles and Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344553/
https://www.ncbi.nlm.nih.gov/pubmed/34137815
http://dx.doi.org/10.1093/cid/ciab554
work_keys_str_mv AT jacobsonkarenb postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT pinskybenjamina postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT montezrathmariae postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT wanghannah postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT millerjacoba postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT skhirimehdi postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT shepardjohn postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT mathewroshni postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT leegrace postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT bohmanbryan postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT parsonnetjulie postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter
AT holubarmarisa postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter